Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions | Zendy

Kaitlin Anstett | Zendy; Thibault Mésplède | Zendy; Maureen Oliveira | Zendy; Vincent Cutillas | Zendy; Mark A. Wainberg | Zendy

Open Access

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

Author(s) -

Kaitlin Anstett,

Thibault Mésplède,

Maureen Oliveira,

Vincent Cutillas,

Mark A. Wainberg

Publication year - 2015

Publication title -

journal of virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.617

H-Index - 292

eISSN - 1070-6321

pISSN - 0022-538X

DOI - 10.1128/jvi.03485-14

Subject(s) - dolutegravir , integrase , biology , integrase inhibitor , virology , drug resistance , mutation , elvitegravir , infectivity , genetics , cross resistance , raltegravir , resistance mutation , virus , human immunodeficiency virus (hiv) , gene , reverse transcriptase , viral load , antiretroviral therapy , rna

The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research